Aerie Pharmaceuticals (AERI) 10-Q2019 Q1 Quarterly report

Filed: 8 May 19, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: acid, arm, Bedminster, beta, biodegradable, blend, blocker, brand, California, Enterprise, ERP, fill, fleet, human, intravitreal, Irvine, Jersey, key, Kingdom, laboratory, leadership, legacy, LIBOR, likelihood, Malta, metabolite, nAMD, neovascular, November, occlusion, opened, opportunity, optimize, oriented, package, pilot, placebo, PLGA, PMDA, poly, reassessing, reassessment, render, renewal, rent, Resource, Roclanda, ROU, RVO, saleable, significantly, study, tier, timepoint, Tokyo, unchanged, underlying, vascular, VEGF, vehicle, vein

Removed: accomplished, adverse, aforementioned, aimed, alternative, anniversary, annum, applied, apply, assessment, ATM, attractive, automatic, back, baseline, Bulletin, Canada, candidate, clarify, collaborative, collateral, collectability, compliance, consisted, consulting, dated, decrease, deducting, deliver, demonstrating, dependent, design, earliest, enacted, enactment, endpoint, equal, evidence, Excluding, expiring, extension, fund, hiring, Historically, hold, IMS, incurrence, inhibiting, input, instrument, intent, investor, involvement, jurisdiction, legislation, Master, minimal, mmHg, modification, modified, noting, order, performed, performing, planned, primary, principle, producing, prospectively, readout, reference, region, registrant, replacement, require, retrospective, revalued, RoclatanTM, SAB, scheduled, seller, setting, short, showed, statistical, subjective, substantial, Subtopic, sudden, summarize, superiority, supplemented, systemic, tenant, thereto, tolerability, unlimited, unpaid, User

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated AERI transcripts

AERI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the filing of the Quarterly Report on Form 10-Q of Aerie Pharmaceuticals, Inc., a Delaware corporation (the “Company”), for the period ended March 31, 2019 (the “Report”), the undersigned, Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board of the Company, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:


(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.




Date: May 8, 2019				/s/ VICENTE ANIDO, JR., PH.D.
				Vicente Anido, Jr., Ph.D.
				Chief Executive Officer, Chairman of the Board
				(Principal Executive Officer)